Step 1: Pirenzepine is a selective M1 muscarinic receptor antagonist (anticholinergic).
Step 2: Blocking M1 receptors on the gastric parietal cell pathway reduces gastric acid secretion, which is therapeutically useful in peptic/gastric ulcer disease.
Step 3: It works in a low therapeutic dose range, sparing other muscarinic-mediated effects, so the indication is gastric ulcer - option (a).
Step 4: Why the others are wrong - glaucoma is treated with cholinergic agonists (pilocarpine) or beta-blockers, not an M1 blocker; hypertension and congestive cardiac failure are managed with antihypertensives and heart-failure drugs, none of which is pirenzepine.